UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 28

Sortiert nach

Clinical inertia in basal insulin-treated patients with type 2 diabetes - Results from a retrospective database study in Japan (JDDM 43)

PloS one, 2018-09, Vol.13 (9), p.e0198160-e0198160

2018

Link zum Volltext

Verfügbarkeit prüfen

DEVOTE 5: Evaluating the Short-Term Cost-Utility of Insulin Degludec Versus Insulin Glargine U100 in Basal–Bolus Regimens for Type 2 Diabetes in the UK

Diabetes therapy, 2018-06, Vol.9 (3), p.1217-1232

2018

Link zum Volltext

Verfügbarkeit prüfen

Redefining Hypoglycemia in Clinical Trials: Validation of Definitions Recently Adopted by the American Diabetes Association/European Association for the Study of Diabetes

Diabetes care, 2020-02, Vol.43 (2), p.398-404

2020

Link zum Volltext

Verfügbarkeit prüfen

Assessment of suicidality in children and adolescents with diagnosis of high functioning autism spectrum disorder in a Turkish clinical sample

Neuropsychiatric disease and treatment, 2016-01, Vol.12, p.2921-2926

2016

Link zum Volltext

Verfügbarkeit prüfen

Target Fasting Plasma Glucose (FPG) without Nocturnal Hypoglycemia in Patients with Type 1 Diabetes or Type 2 Diabetes—Results from SWITCH Trials

Diabetes (New York, N.Y.), 2018-07, Vol.67 (Supplement_1)

2018

Link zum Volltext

Verfügbarkeit prüfen

Oral orismilast: Efficacy and safety in moderate‐to‐severe psoriasis and development of modified release tablets

Journal of the European Academy of Dermatology and Venereology, 2023-04, Vol.37 (4), p.711-720

2023

Link zum Volltext

Verfügbarkeit prüfen

Pharmacology of orismilast, a potent and selective PDE4 inhibitor

Journal of the European Academy of Dermatology and Venereology, 2023-04, Vol.37 (4), p.721-729

2023

Link zum Volltext

Verfügbarkeit prüfen

The rate of hyperglycemia and ketosis with insulin degludec‐based treatment compared with insulin detemir in pediatric patients with type 1 diabetes: An analysis of data from two randomized trials

Pediatric diabetes, 2019-05, Vol.20 (3), p.314-320

2019

Link zum Volltext

Verfügbarkeit prüfen

The co‐formulation of insulin degludec and insulin aspart lowers fasting plasma glucose and rates of confirmed and nocturnal hypoglycaemia, independent of baseline glycated haemoglobin levels, disease duration or body mass index: A pooled meta‐analysis of phase III studies in patients with type 2 diabetes

Diabetes, obesity & metabolism, 2018-07, Vol.20 (7), p.1585-1592

2018

Link zum Volltext

Verfügbarkeit prüfen

Short‐term cost‐utility of degludec versus glargine U100 for patients with type 2 diabetes at high risk of hypoglycaemia and cardiovascular events: A Canadian setting (DEVOTE 9)

Diabetes, obesity & metabolism, 2019-07, Vol.21 (7), p.1706-1714

2019

Link zum Volltext

Verfügbarkeit prüfen

Cost analysis of insulin degludec in comparison with insulin detemir in treatment of children and adolescents with type 1 diabetes in the UK

BMJ open diabetes research & care, 2019, Vol.7 (1), p.e000664-e000664

2019

Link zum Volltext

Verfügbarkeit prüfen

Characteristics of Children Who Lost the Diagnosis of Autism: A Sample from Istanbul, Turkey

Autism Research and Treatment, 2014-01, Vol.2014 (2014), p.472120-10

2014

Link zum Volltext

Verfügbarkeit prüfen

Long-term Cost-effectiveness of Insulin Degludec Versus Insulin Glargine U100 in the UK: Evidence from the Basal-bolus Subgroup of the DEVOTE Trial (DEVOTE 16)

Applied health economics and health policy, 2019-10, Vol.17 (5), p.615-627

2019

Link zum Volltext

Verfügbarkeit prüfen

147 - Risk Reductions across Hypoglycemia Definitions with Insulin Degludec (IDeg) vs. Insulin Glargine U100 (IGlar) in SWITCH 1 and 2

Canadian journal of diabetes, 2017-10, Vol.41 (5), p.S57-S58

2017

Link zum Volltext

Verfügbarkeit prüfen

Risk Reductions across Hypoglycemia Definitions with Insulin Degludec (IDeg) vs. Insulin Glargine U100 (IGlar) in SWITCH 1 and 2

Canadian journal of diabetes, 2017-10, Vol.41 (5), p.S57-S58

2017

Link zum Volltext

Verfügbarkeit prüfen

Short-Term Cost-Effectiveness of Insulin Degludec vs. Insulin Glargine 100 Units/mL for Patients with Type 2 Diabetes at High Risk of Hypoglycemia in DEVOTE

Canadian journal of diabetes, 2018-10, Vol.42 (5), p.S60

2018

Link zum Volltext

Verfügbarkeit prüfen

179 - Short-Term Cost-Effectiveness of Insulin Degludec vs. Insulin Glargine 100 Units/mL for Patients with Type 2 Diabetes at High Risk of Hypoglycemia in DEVOTE

Canadian journal of diabetes, 2018-10, Vol.42 (5), p.S60-S60

2018

Link zum Volltext

Verfügbarkeit prüfen

Healthcare Resource Utilization and Costs Associated with Ketosis Events in Pediatric and Adult Patients with Type 1 Diabetes Mellitus in the UK

Diabetes therapy, 2017-10, Vol.8 (5), p.1065-1078

2017

Link zum Volltext

Verfügbarkeit prüfen

Achieving FPG Target Without Hypoglycemia: A Meta-Analysis of Insulin Degludec vs. Insulin Glargine U100

Canadian journal of diabetes, 2016-10, Vol.40 (5), p.S56-S56

2016

Link zum Volltext

Verfügbarkeit prüfen

153 - Achieving FPG Target Without Hypoglycemia: A Meta-Analysis of Insulin Degludec vs. Insulin Glargine U100

Canadian journal of diabetes, 2016-10, Vol.40 (5), p.S56-S56

2016

Link zum Volltext

Verfügbarkeit prüfen

Asperger's disorder and Williams syndrome: a case report

Turkish journal of pediatrics, 2011-05, Vol.53 (3), p.352-355

2011

Link zum Volltext

Verfügbarkeit prüfen

Effects of Atomoxetine in Individuals with Attention-Deficit/Hyperactivity Disorder and Low-Functioning Autism Spectrum Disorder

Journal of child and adolescent psychopharmacology, 2016-11, Vol.26 (9), p.798

2016

Link zum Volltext

Verfügbarkeit prüfen

OROS methylphenidate-induced skin eruptions

Journal of child and adolescent psychopharmacology, 2009-10, Vol.19 (5), p.593

2009

Link zum Volltext

Verfügbarkeit prüfen

Long Acting Risperidone in an Adolescent with Conduct Disorder: A Case Report

Psychopharmacology bulletin, 2011-09, Vol.44 (3), p.69-72

2011

Link zum Volltext

Verfügbarkeit prüfen

Complementary and alternative treatments of attention deficit hyperactivity disorder/Dikkat eksikligi hiperaktivite bozuklugunda tamamlayici ve alternatif tedaviler

Noro-Psikiyatri Arsivi, 2011-06, Vol.48 (2), p.94

2011

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 28

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(22)
Mit Volltextzugriff
(25)

Publikationsform

Artikel
(28)

Sprache

Englisch
(28)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(17)
Life Sciences & Biomedicine
(16)
Humans
(12)
Diabetes
(10)
Insulin
(10)
Endocrinology & Metabolism
(8)
Male
(8)
Hypoglycemia
(7)
Diabetes Mellitus
(6)
Female
(6)
Patients
(6)
Adolescent
(5)
Child
(5)
Clinical Trials
(5)
Hypoglycemic Agents - Therapeutic Use
(5)
Pediatrics
(5)
Psychiatry
(5)
Care And Treatment
(4)
Diabetes Mellitus, Type 2 - Drug Therapy
(4)
Glucose
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Clinical inertia in basal insulin-treated patients with type 2 diabetes - Results from a retrospective database study in Japan (JDDM 43)

DEVOTE 5: Evaluating the Short-Term Cost-Utility of Insulin Degludec Versus Insulin Glargine U100 in Basal–Bolus Regimens for Type 2 Diabetes in the UK

Redefining Hypoglycemia in Clinical Trials: Validation of Definitions Recently Adopted by the American Diabetes Association/European Association for the Study of Diabetes

Assessment of suicidality in children and adolescents with diagnosis of high functioning autism spectrum disorder in a Turkish clinical sample

Target Fasting Plasma Glucose (FPG) without Nocturnal Hypoglycemia in Patients with Type 1 Diabetes or Type 2 Diabetes—Results from SWITCH Trials

Oral orismilast: Efficacy and safety in moderate‐to‐severe psoriasis and development of modified release tablets

Pharmacology of orismilast, a potent and selective PDE4 inhibitor

The rate of hyperglycemia and ketosis with insulin degludec‐based treatment compared with insulin detemir in pediatric patients with type 1 diabetes: An analysis of data from two randomized trials

Short‐term cost‐utility of degludec versus glargine U100 for patients with type 2 diabetes at high risk of hypoglycaemia and cardiovascular events: A Canadian setting (DEVOTE 9)

Cost analysis of insulin degludec in comparison with insulin detemir in treatment of children and adolescents with type 1 diabetes in the UK

Characteristics of Children Who Lost the Diagnosis of Autism: A Sample from Istanbul, Turkey

Long-term Cost-effectiveness of Insulin Degludec Versus Insulin Glargine U100 in the UK: Evidence from the Basal-bolus Subgroup of the DEVOTE Trial (DEVOTE 16)

147 - Risk Reductions across Hypoglycemia Definitions with Insulin Degludec (IDeg) vs. Insulin Glargine U100 (IGlar) in SWITCH 1 and 2

Risk Reductions across Hypoglycemia Definitions with Insulin Degludec (IDeg) vs. Insulin Glargine U100 (IGlar) in SWITCH 1 and 2

Short-Term Cost-Effectiveness of Insulin Degludec vs. Insulin Glargine 100 Units/mL for Patients with Type 2 Diabetes at High Risk of Hypoglycemia in DEVOTE

179 - Short-Term Cost-Effectiveness of Insulin Degludec vs. Insulin Glargine 100 Units/mL for Patients with Type 2 Diabetes at High Risk of Hypoglycemia in DEVOTE

Healthcare Resource Utilization and Costs Associated with Ketosis Events in Pediatric and Adult Patients with Type 1 Diabetes Mellitus in the UK

Achieving FPG Target Without Hypoglycemia: A Meta-Analysis of Insulin Degludec vs. Insulin Glargine U100

153 - Achieving FPG Target Without Hypoglycemia: A Meta-Analysis of Insulin Degludec vs. Insulin Glargine U100

Asperger's disorder and Williams syndrome: a case report

Effects of Atomoxetine in Individuals with Attention-Deficit/Hyperactivity Disorder and Low-Functioning Autism Spectrum Disorder

OROS methylphenidate-induced skin eruptions

Long Acting Risperidone in an Adolescent with Conduct Disorder: A Case Report

Complementary and alternative treatments of attention deficit hyperactivity disorder/Dikkat eksikligi hiperaktivite bozuklugunda tamamlayici ve alternatif tedaviler

Suchergebnisse filtern